Key Highlights

  • Zymeworks (NASDAQ:ZYME) traded near USD 27.25 early on Wednesday, October 21, 2026, close to the top of a 52-week range of about USD 16.00 to USD 31.34, after completing its Theravance Biopharma acquisition.
  • The acquisition closed on Wednesday, September 23, 2026, adding cash flow from YUPELRI, an inhaled treatment for chronic obstructive pulmonary disease, and was funded partly by USD 350 million of senior secured notes.
  • Updated 2026 guidance followed on Monday, September 28. Third-quarter results are due after the close on Monday, November 9, 2026, with no conference call, ahead of four investor conferences.
  • The 105.54% rise in basic earnings per share in market data reflects partner income on a still loss-making trailing base, so it is a narrowing loss rather than settled profitability.

An Acquisition Reshapes the Company

Zymeworks (NASDAQ:ZYME) is a biotechnology company that discovered Ziihera (zanidatamab), a HER2-targeted bispecific antibody, meaning one that binds two targets, commercialised by Jazz Pharmaceuticals (NASDAQ:JAZZ) and BeOne Medicines (NASDAQ:ONC). It completed the acquisition of Theravance Biopharma on Wednesday, September 23, 2026, adding YUPELRI (revefenacin) and its cash flow, and issued updated 2026 guidance on Monday, September 28. The deal was valued at about USD 929 million and was financed partly with USD 350 million of senior secured notes. The shares closed at USD 24.77 on Wednesday, October 14, 2026 and traded near USD 27.25 early on Wednesday, October 21, for a market value of about USD 1.95 billion. The company had not issued a release accounting for the recent gain as of October 21.

How the Earnings Mix Is Changing

Zymeworks (NASDAQ:ZYME) has relied on partner payments, meaning milestones tied to regulatory and commercial events, and royalties on Ziihera sales, which make earnings lumpy. The 105.54% earnings improvement in market data reflects that income set against research costs on a negative trailing base, so it is a narrowing loss and partly a timing effect of milestones rather than durable operating growth. Theravance changes the mix by adding a recurring product revenue stream from YUPELRI, and the company describes a royalty aggregation strategy, which pools royalties from several partnered products. Pasritamig, a multispecific antibody built on the Azymetric platform, is in clinical development at Johnson & Johnson (NYSE:JNJ). The new secured notes add interest costs, so free cash flow, not reported earnings, becomes the cleaner test.

Risks and What to Watch

The first risk for Zymeworks (NASDAQ:ZYME) is integration: YUPELRI cash flow must meet the updated guidance while the company absorbs a new commercial unit, led by Suzanne Monahan as general manager. The second is leverage, since USD 350 million of senior secured notes require interest payments in a period of rising policy rates. The third is partner dependence, as Ziihera royalties and milestones depend on commercial execution and trial outcomes at Jazz Pharmaceuticals and BeOne Medicines. Investors should watch the Federal Reserve decision on Wednesday, October 28, 2026, third-quarter results after the close on Monday, November 9, 2026 and fireside chats at the Wolfe Research conference on Tuesday, November 10, Stifel on Wednesday, November 11 and Jefferies on Tuesday, November 17.

Where Things Stand

The answer is that Theravance gives Zymeworks (NASDAQ:ZYME) a recurring cash stream from YUPELRI, which could make earnings less dependent on lumpy partner milestones. The shares near USD 27.25 sit about 13% below the 52-week high, so much of that shift appears priced. The next catalysts are third-quarter results on November 9, the first figures including Theravance, and November conference appearances. Guidance figures are estimates, not guarantees, and this is not investment advice.